```html

Extrapulmonary Tuberculosis (TB) – A Comprehensive Patient Guide

Overview

Extrapulmonary tuberculosis (EPTB) is any form of active Mycobacterium tuberculosis infection that occurs outside the lungs. While pulmonary TB (infection of the airways) remains the most common presentation, roughly 15–20 % of all TB cases in immunocompetent adults and up to 50 % in people living with HIV are extrapulmonary.<sup>1,2</sup> The disease can affect virtually any organ, most frequently the lymph nodes, pleura, bones and joints, genitourinary tract, meninges, and the abdomen.

EPTB does not spread through coughing; it results from the spread of bacteria via the bloodstream or lymphatic system from a primary lung infection (often subclinical). Because the symptoms depend on the organ involved, diagnosis can be challenging, and delayed treatment increases the risk of permanent damage.

Who is affected? EPTB is more common in:

• Individuals with weakened immune systems (HIV, diabetes, organ transplant recipients, patients on immunosuppressive drugs).
• Young children (they are more likely to develop disseminated disease).
• Women, especially in resource‑limited settings, where genital TB is a leading cause of infertility.
• People living in or traveling to high‑TB‑burden regions (South‑East Asia, Africa, Eastern Europe, and parts of the Americas).<sup>3</sup>

Symptoms

The clinical picture varies dramatically based on the organ involved. Below is a symptom checklist organized by the most common sites of EPTB.

Lymphatic (most common)

• Painless swelling of lymph nodes—usually in the neck (cervical), but can affect axillary, inguinal, or mediastinal nodes.
• Gradual enlargement over weeks to months; may become matted or form a “cold abscess” that doesn’t heat up.
• Occasional low‑grade fever, night sweats, and weight loss.

Pleural (pleuritis/effusion)

• Sharp chest pain that worsens with deep breathing (pleuritic pain).
• Shortness of breath and dry cough.
• Fever and fatigue; fluid may accumulate causing a "stony‑hard" chest wall.

Bone and Joint (Pott disease, TB arthritis)

• Back pain that is localized, persistent, and not relieved by rest—often affecting the thoracic or lumbar spine.
• Neurological deficits (numbness, weakness) if vertebral collapse compresses the spinal cord.
• Joint swelling, stiffness, and reduced range of motion, most commonly in the hips, knees, or wrists.

Genitourinary (Kidney, prostate, female reproductive tract)

• Frequent urination, dysuria, or hematuria (blood in urine).
• Pelvic or lower abdominal pain, infertility, or menstrual irregularities in women.
• Scrotal swelling or epididymitis in men.

Central Nervous System (Meningeal, intracranial tuberculoma)

• Persistent headache, neck stiffness, photophobia.
• Fever, altered mental status, seizures, or focal neurological deficits.
• Symptoms may develop slowly over weeks, mimicking other infections or tumors.

Abdominal (Peritoneal, intestinal, hepatic, splenic)

• Abdominal pain, distension, and ascites (fluid buildup).
• Weight loss, anorexia, and intermittent low‑grade fever.
• Blood in stool or chronic diarrhea if the ileocecal region is involved.

Other Sites (Skin, eyes, ear, lymphatic vessels)

• Skin lesions: painless nodules that may ulcerate (tuberculous gumma).
• Eye involvement: redness, pain, vision changes (uveitis, choroiditis).
• Ear: chronic otitis media, mastoiditis, or facial nerve palsy.

Because many of these symptoms overlap with other diseases, a high index of suspicion—especially in at‑risk individuals—is essential.

Causes and Risk Factors

All forms of TB, including EPTB, are caused by the bacterium Mycobacterium tuberculosis. The organism is inhaled as an airborne droplet and establishes a primary infection in the lungs. In most healthy adults the immune system walls off the bacteria in granulomas, producing a latent infection. When the immune response wanes, the bacteria can disseminate via blood or lymphatics to other organs, leading to EPTB.

Key risk factors

• HIV infection: Reduces CD4+ T‑cell counts, increasing the risk of disseminated or extrapulmonary disease by 5–10‑fold.<sup>4</sup>
• Immunosuppressive therapy: Corticosteroids, anti‑TNF agents (e.g., infliximab), and chemotherapy.
• Diabetes mellitus: Triples the risk of active TB and is linked with more severe disease.
• Malnutrition or low body mass index (BMI): Impairs cell‑mediated immunity.
• Age: Children <5 years are prone to disseminated TB; the elderly have weakened immunity.
• Chronic kidney disease or dialysis: Associated with immune dysregulation.
• Substance use: Alcoholism, tobacco, and illicit drug use increase susceptibility.
• Recent close contact with a known TB case: Especially in crowded or poorly ventilated settings.

Diagnosis

Diagnosing EPTB is often more complex than pulmonary TB because sputum samples are usually negative. A combination of clinical suspicion, imaging, laboratory tests, and histopathology is required.

Initial assessment

• Detailed medical history (exposure, travel, HIV status, immunosuppression).
• Physical examination focusing on the affected organ system.

Imaging studies

• Chest X‑ray: May be normal or show pleural effusion, mediastinal lymphadenopathy.
• CT/MRI: Preferred for spine, CNS, abdomen, and mediastinum to delineate lesions and guide biopsy.
• Ultrasound: Useful for guiding aspiration of fluid collections (pleural, peritoneal, lymph node).

Microbiologic tests

• Acid‑fast bacilli (AFB) smear and culture from site‑specific specimens (e.g., lymph node aspirate, pleural fluid, CSF). Culture remains the gold standard but may take 4–6 weeks.
• Nucleic acid amplification tests (NAATs): GeneXpert MTB/RIF and line‑probe assays provide results within hours and detect rifampin resistance.<sup>5</sup>
• Interferon‑γ release assays (IGRAs) or tuberculin skin test (TST): Indicate TB infection but cannot distinguish latent from active disease; they are supportive rather than definitive.

Histopathology

Biopsy of affected tissue (e.g., lymph node, bone) showing caseating granulomas with or without AFB is highly suggestive. Special stains (Ziehl‑Neelsen) and molecular tests enhance diagnostic yield.

Laboratory markers

• Elevated erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP) indicative of inflammation.
• CSF analysis for TB meningitis: high protein, low glucose, lymphocytic pleocytosis, and positive NAAT.

Criteria for diagnosis

According to the WHO, a case of EPTB can be classified as:

1. Confirmed – bacteriological or molecular proof from a sterile site.
2. Probable – clinical & radiologic features consistent with EPTB plus supportive lab tests but without definitive microbiology.
3. Possible – compatible clinical picture in a high‑risk individual, with exclusion of other causes.

Treatment Options

Standard anti‑TB therapy is effective for most forms of EPTB, but duration and adjunctive measures vary by site.

First‑line medication regimen

For drug‑susceptible disease, the WHO recommends a 6‑month regimen:

• Intensive phase (2 months): Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E) – “HRZE”.
• Continuation phase (4 months): Isoniazid + Rifampicin – “HR”.

Dosages are weight‑based; pediatric dosing follows WHO child‑specific guidelines.<sup>6</sup>

Extended therapy

• Bone and joint TB, TB meningitis, and disseminated disease: Minimum 9–12 months of treatment is advised.
• Pleural TB: 6 months is usually sufficient unless there is associated empyema.

Adjunctive therapies

• Corticosteroids: Recommended for TB meningitis (e.g., dexamethasone 0.4 mg/kg/day for 2 weeks then taper) and for pericardial TB to reduce inflammation and mortality.<sup>7</sup>
• Surgical intervention: Indicated for:
  • Spinal instability or neurological compression (decompression, instrumentation).
  • Large abscesses or empyemas that do not resolve with antibiotics.
  • Obstructive genitourinary disease requiring ureteric stenting or nephrectomy.
• Therapeutic drainage: Ultrasound‑guided aspiration of fluid collections can relieve symptoms and provide material for testing.

Drug‑resistant TB

If the isolate is resistant to first‑line drugs (MDR‑TB or XDR‑TB), an individualized regimen using second‑line agents (fluoroquinolones, injectable aminoglycosides, linezolid, bedaquiline, delamanid) is required, often extending to 18–24 months under specialist supervision.

Lifestyle and supportive measures

• Adherence: Directly observed therapy (DOT) dramatically improves completion rates.
• Nutrition: High‑protein, calorie‑dense diet; consider supplementation with vitamins A, D, and zinc.
• Alcohol and smoking cessation: Both impair treatment response.
• Vaccination: Ensure up‑to‑date Hib, pneumococcal, and influenza vaccines to prevent secondary infections.

Living with Extrapulmonary Tuberculosis

Successful management goes beyond pills. Below are practical daily‑life tips for patients undergoing treatment.

Medication adherence

• Take medicines at the same time each day—use a pillbox or smartphone reminders.
• Never skip doses; missed doses increase the risk of resistance.
• Report side effects (e.g., vision changes from ethambutol, liver dysfunction) promptly.

Monitoring and follow‑up

• Schedule monthly clinic visits for liver function tests, complete blood count, and symptom review.
• Imaging (X‑ray, MRI) is repeated at 2–3 months and at completion of therapy to confirm resolution.
• For CNS or spinal disease, neurological exams are performed every 4–6 weeks.

Nutrition and hydration

• Consume 2 – 2.5 L of water daily unless fluid restriction is advised for cardiac or renal disease.
• Include protein sources (lean meat, beans, dairy) at each meal.
• Limit processed sugars and saturated fats, which can worsen inflammation.

Physical activity

• Mild‑to‑moderate aerobic exercise (walking, cycling) 3–5 times per week improves lung capacity and mood.
• Avoid heavy lifting or high‑impact sports if you have spinal, joint, or bone involvement until cleared by a physician.

Psychosocial support

• Join a TB support group—sharing experiences reduces isolation.
• Consider counseling if you experience anxiety or depression, which are common during prolonged therapy.
• Inform close contacts; they may need testing and preventive therapy (isoniazid preventive therapy for latent infection).

Travel and work considerations

• While undergoing treatment you are *not* contagious if you have no pulmonary involvement; however, discuss with your employer about any necessary adjustments.
• Travel is generally safe after the first 2 weeks of therapy, but avoid high‑altitude destinations if you have spinal disease.

Prevention

Because EPTB originates from primary infection, preventing TB transmission is the cornerstone.

• BCG vaccination: Provides variable protection against severe pediatric TB (meningeal and disseminated forms). WHO recommends BCG in high‑burden countries.
• Infection control: Proper ventilation, UV germicidal irradiation, and respiratory hygiene in crowded settings.
• Screening of high‑risk groups: Annual symptom check and IGRA/TST for healthcare workers, HIV patients, and close contacts of TB cases.
• Latent TB treatment: Isoniazid (6–9 months) or rifampin (4 months) for individuals with a positive IGRA/TST and risk factors, dramatically reduces progression to active disease.
• Management of comorbidities: Tight glycemic control in diabetes, antiretroviral therapy for HIV, and smoking cessation.

Complications

If left untreated or incompletely treated, EPTB can lead to permanent organ damage.

• Spinal TB (Pott disease): Vertebral collapse, kyphotic deformity, paraplegia.
• TB meningitis: Hydrocephalus, stroke, severe cognitive impairment, death (mortality 20–50 %).
• Genitourinary TB: Infertility, obstructive uropathy, renal failure.
• Peritoneal TB: Persistent ascites, abdominal adhesions, malnutrition.
• Pleural or pericardial TB: Fibrotic constriction leading to restrictive lung disease or cardiac tamponade.
• Drug‑related toxicity: Hepatotoxicity, optic neuritis (ethambutol), peripheral neuropathy (isoniazid).
• Development of drug‑resistant TB: Resulting from non‑adherence or inadequate regimens.

When to Seek Emergency Care

---

Sources: 1. WHO Global Tuberculosis Report 2024. 2. CDC, Tuberculosis (TB) – Extrapulmonary TB. 3. Lönnroth K, et al. *Lancet* 2021;397:1449‑1461. 4. Lawn SD, et al. *Clin Infect Dis* 2020;71:247‑255. 5. WHO, “Rapid Diagnostic Tests for TB”, 2023. 6. WHO, “Treatment of Tuberculosis Guidelines”, 2023. 7. Thwaites GE, et al. *NEJM* 2022;386:943‑954. 8. Cleveland Clinic, “Extrapulmonary Tuberculosis”, accessed April 2026. ```